Price
$44.22
Increased by +1.73%
Dollar volume (20D)
34.39 M
ADR%
3.69
Earnings report date
Feb 13, 2025
Shares float
89.01 M
Shares short
3.38 M [3.80%]
Shares outstanding
92.34 M
Market cap
4.01 B
Beta
0.58
Price/earnings
N/A
20D range
41.45 50.00
50D range
41.45 57.99
200D range
37.02 60.37

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally.

Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.

The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III.

Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

  • Quarterly earnings
  • Annual earnings
Reported date EPSChange YoY EstimateSurprise
Nov 5, 24 -1.40
Increased by +37.22%
-1.45
Increased by +3.45%
Aug 1, 24 -1.52
Increased by +32.44%
-1.69
Increased by +10.06%
May 2, 24 -2.03
Increased by +12.88%
-1.73
Decreased by -17.34%
Feb 15, 24 -1.52
Increased by +29.63%
-1.62
Increased by +6.17%
Nov 2, 23 -2.23
Increased by +36.29%
-2.08
Decreased by -7.21%
Aug 3, 23 -2.25
Increased by +0.44%
-2.07
Decreased by -8.70%
May 4, 23 -2.33
Decreased by -6.39%
-1.98
Decreased by -17.68%
Feb 16, 23 -2.16
Decreased by -20.67%
-2.14
Decreased by -0.93%
  • Quarterly financials
  • Annual financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 24 139.49 M
Increased by +42.27%
-133.52 M
Increased by +16.37%
Decreased by -95.71%
Increased by +41.21%
Jun 30, 24 147.03 M
Increased by +35.75%
-131.60 M
Increased by +17.66%
Decreased by -89.51%
Increased by +39.34%
Mar 31, 24 108.83 M
Increased by +8.30%
-170.68 M
Decreased by -4.09%
Decreased by -156.83%
Increased by +3.88%
Dec 31, 23 127.39 M
Increased by +23.27%
-123.19 M
Increased by +18.86%
Decreased by -96.70%
Increased by +34.18%
Sep 30, 23 98.05 M
Increased by +8.10%
-159.65 M
Increased by +34.87%
Decreased by -162.82%
Increased by +39.75%
Jun 30, 23 108.31 M
Increased by +21.23%
-159.83 M
Decreased by -1.05%
Decreased by -147.57%
Increased by +16.64%
Mar 31, 23 100.50 M
Increased by +25.72%
-163.97 M
Decreased by -7.65%
Decreased by -163.16%
Increased by +14.37%
Dec 31, 22 103.35 M
Increased by +23.93%
-151.83 M
Decreased by -23.99%
Decreased by -146.91%
Decreased by -0.04%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY